Respiratory Papillomatosis clinical trials at University of California Health

• A Study of Experimental INO-3107 With Electroporation (EP) in HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

  open to eligible people ages 18 years and up

  This is a Phase 1/2 open-label, multicenter trial to evaluate the safety, tolerability, immunogenicity, and efficacy of INO-3107 in subjects with HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis (RRP). The trial population will include participants who have been diagnosed with either Juvenile-Onset RRP (J-O RRP) as defined by age at first diagnosis <12 years or with Adult- Onset RRP (A-O RRP) as defined by age at first diagnosis ≥12 years. A safety run-in will be performed with up to six participants with a one week waiting period between each enrolled participant.

  at UC Davis

Last updated: August 18, 2021